Description
EXERCISE OPTION YEAR 4 - BPA 36E79722A0020
Base award description: BPA FOR LIVMARLI
First action · last action
2022-05-02 · 2026-04-03
Transactions
13
First transaction's obligation
$0
Base + all options value (sum of deltas)
$1,125,000
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79722D0112
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 13 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-05-02+$0= $0
- Mod P000012022-12-05+$0= $0
- Mod P000022023-03-06+$0= $0
- Mod P000032023-12-06+$0= $0
- Mod P000042024-03-11+$0= $0
- Mod P000052024-12-05+$0= $0
- Mod P000062024-12-05+$0= $0
- Mod P000072025-03-18+$0= $0
- Mod P000082025-03-18+$0= $0
- Mod P000092025-12-10+$0= $0
- Mod P000102025-12-12+$0= $0
- Mod P000112026-04-02+$0= $0
- Mod P000122026-04-03+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-05-02 | +$0 | $0 | BPA FOR LIVMARLI |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-12-05 | +$0 | $0 | 2023 PUBLIC LAW PRICING UPDATES |
| Mod P00002· EXERCISE AN OPTION | 2023-03-06 | +$0 | $0 | EXERCISE OPTION YEAR 1 ON BPA 36E79722A0020 |
| Mod P00003· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2023-12-06 | +$0 | $0 | 2024 PUBLIC LAW PRICING UPDATES |
| Mod P00004· EXERCISE AN OPTION | 2024-03-11 | +$0 | $0 | EXERCISE OPTION YEAR 2 ON BPA 36E79722A0020 |
| Mod P00005· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-12-05 | +$0 | $0 | MODIFICATION TO INCORPORATE THE PRODUCT ADDITION OF 2 CHOLBAM NDCS TO BPA 36E79722A0020. |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-12-05 | +$0 | $0 | 2025 PL PRICE UPDATE |
| Mod P00007· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-03-18 | +$0 | $0 | PRODUCT ADDITION - LIVMARLI |
| Mod P00008· EXERCISE AN OPTION | 2025-03-18 | +$0 | $0 | EXERCISE OPTION YEAR 3 ON BPA 36E79722A0020. |
| Mod P00009· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-12-10 | +$0 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE THE ADDITION OF 2 CHOLBAM NDCS AND 4 LIVMARLI NDCS ON BPA 36E79722A… |
| Mod P00010· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-12-12 | +$0 | $0 | 2026 PUBLIC LAW PRICING UPDATES. |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-04-02 | +$0 | $0 | MODIFICATION TO INCORPORATE 1 NDC ADDITION |
| Mod P00012· EXERCISE AN OPTION | 2026-04-03 | +$0 | $0 | EXERCISE OPTION YEAR 4 - BPA 36E79722A0020 |
Related awards · 9
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI U8E2HFXRE9X3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25025P1221 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6505 · DRUGS AND BIOLOGICALS | $227,874 | FY2025 |
| 36C25025P0648 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 3650 · CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY | $231,717 | FY2025 |
| 36F79722D0112 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36F79722D004E | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79722A0020_3600 · retrieved 2026-09-26.